Astellas Reduces Universal Cells Workforce in Seattle, Relocates 12 Positions to Japan

Layoffs and Transfers:
Astellas has cut 24 roles at Universal Cells in Seattle and transferred 12 positions to Japan as part of its restructuring efforts.

Background:
Universal Cells is a Seattle-based biotech company specializing in engineered, allogeneic stem cells for therapeutic applications.

Industry Context:
The biotech industry has seen a wave of layoffs in 2024, with several companies reducing their workforce to manage costs and focus on strategic priorities.

Astellas' Involvement:
Astellas acquired Universal Cells six years ago and has been involved in various cell therapy clinical trials, including those using human pluripotent stem cells (hPSCs).

Impact:
The layoffs and transfers reflect broader challenges in the biotech sector, including the need to streamline operations and prioritize resources in a competitive and rapidly evolving field.